Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSCORE-HCC trial of atezolizumab + bevacizumab with radiotherapy in unresectable hepatocellular carcinoma
jRCT1051250211Recruiting
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC). Primary endpoint: Incidence of Grade 3 or higher treatment-related adverse events within 8 weeks after radiotherapy completion. Started Mar 2026; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1051250211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250211.